By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for HRS-6093, its novel oral KRAS G12D inhibitor, along with multiple combination regimens involving five additional proprietary compounds: SHR-9839 (sc), SHR-1826, adebrelimab, SHR-8068, and FH-006. The approval enables evaluation of these combinations in advanced malignant solid tumors harboring KRAS G12D mutations, one of the most challenging oncogenic drivers to target therapeutically.
Lead Compound Profile: HRS-6093
| Parameter | Detail |
|---|---|
| Compound | HRS-6093 |
| Mechanism | Novel, potent, and selective oral KRAS G12D inhibitor |
| Target Specificity | Specifically binds to KRAS G12D mutant protein |
| Administration | Oral |
| Therapeutic Area | Advanced malignant solid tumors with KRAS G12D mutations |
KRAS G12D represents a historically “undruggable” target that has eluded therapeutic intervention for decades, making HRS-6093 a potentially transformative agent for patients with this specific mutation profile.
Combination Portfolio Details
The NMPA approval encompasses multiple strategic combination approaches:
Immunotherapy Combinations
- HRS-6093 + adebrelimab (anti-PD-1 mAb, approved in China 2023) ± chemotherapy
- HRS-6093 + adebrelimab + SHR-8068 (anti-CTLA-4 mAb) ± bevacizumab
- HRS-6093 + SHR-9839 (sc) ± adebrelimab or ± chemotherapy
Targeted Therapy Combinations
- HRS-6093 + bevacizumab ± adebrelimab
- HRS-6093 + SHR-1826 (c-Met ADC) or FH-006 ± adebrelimab
- HRS-6093 + cetuximab ± chemotherapy
Individual Compound Profiles
- SHR-9839 (sc): Subcutaneously injected humanized mAb blocking two key tumor signaling pathways
- SHR-1826: c-Met-targeting antibody-drug conjugate (ADC) with tumor-specific internalization
- Adebrelimab: Anti-PD-1 mAb approved for marketing in China (2023)
- SHR-8068: Fully human anti-CTLA-4 mAb enhancing anti-tumor immune effects
Strategic & Scientific Significance
- KRAS G12D Market Opportunity: Represents approximately 10-15% of pancreatic cancers, 5-8% of colorectal cancers, and significant subsets of other solid tumors
- Platform Validation: Demonstrates Hengrui’s integrated drug discovery capabilities across small molecules, monoclonal antibodies, and ADCs
- Combination Strategy: Addresses tumor heterogeneity and resistance mechanisms through multi-modal approaches targeting complementary pathways
- Competitive Positioning: Positions Hengrui among the vanguard of companies developing KRAS G12D inhibitors globally
- Commercial Pipeline: Leverages existing approved assets (adebrelimab) while advancing next-generation candidates
This comprehensive clinical program reflects Hengrui’s strategy of developing precision medicine approaches for genetically defined patient populations while maximizing the value of its proprietary pipeline through rational combination strategies.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and therapeutic potential. Actual results may differ due to risks including clinical trial outcomes, safety findings, regulatory decisions, and competitive dynamics in the oncology space.-Fineline Info & Tech